Surgery Partners posts Q3 net loss of $21.1 million; revenue falls to $815.3 million
SGRY•Surgery Partners reported a third-quarter 2026 net loss attributable to the company of $21.1 million, while revenue fell year over year to $815.3 million. Operating cash flow rose 24% to $103.5 million, and an amended merger agreement raises cash consideration to $25 per share.
1. Quarterly results
Surgery Partners reported a third-quarter 2026 net loss attributable to the company of $21.1 million. Revenue fell year over year to $815.3 million, while operating cash flow climbed 24% to $103.5 million.
2. Merger agreement
The amended HealthSpan Partners merger agreement raises cash consideration to $25 per share, valuing the enterprise at up to approximately $6 billion. The merger remains expected to close in the first quarter of 2027, subject to stockholder and regulatory approvals and customary conditions.
